Clinical Trial Update: A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating rivaroxaban (JNJ-39039039) for reducing venous thromboembolism risk after hospital discharge; study completed with results posted in …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure
• Respiratory Insufficiency

Drugs mentioned

• Rivaroxaban (rivaroxaban)

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Heart Failure, Respiratory Insufficiency | Phase 3 | Status: COMPLETED | Results posted: 2019-11-25